Table V.
Distribution of genotypes and alleles among monotherapy-responsive and monotherapy-resistant group
| Variable | Monotherapy responder* | Monotherapy resistant* | P-value | aOR (95% CI) | P-value |
|---|---|---|---|---|---|
| Genotype: | 0.008 | ||||
| G/G | 18 (18.9) | 1 (2.9) | Reference | ||
| A/G | 74 (77.9) | 29 (82.9) | 6.83 (0.87–53.73) | 0.068 | |
| A/A | 3 (3.2) | 5 (14.3) | 32.43 (2.68–272.73) | 0.006 | |
| A/A vs. A/G | 5.07 (1.05–24.40) | 0.043 | |||
| Genotype: | 0.021 | ||||
| G/G | 18 (18.9) | 1 (2.9) | Reference | ||
| A/G or A/A | 77 (81.1) | 34 (97.1) | 7.96 (1.02–62.26) | 0.048 | |
| Allele: | 0.051 | ||||
| G | 110 (57.9) | 31 (44.3) | Reference | ||
| A | 80 (42.1) | 39 (55.7) | 1.73 (1.00–3.02) | 0.050 |
*
Data are expressed as number of patients and percentage (%); aOR – adjusted odds ratio for gender and age. Statistical significant association of IVS5-91 rs 3812718 G>A polymorphism and monotherapy-resistant epilepsy. Significant differences are bolded.